T-cell activation, senescence, and exhaustion in asymptomatic HIV/Leish*mania infantum* co-infection

3 Short title: immune response in HIV/Leishmania coinfection

5	Carolina de Oliveira Mendes-Aguiar ^{1+¶} , Manoella do Monte Alves ^{1,2,3+¶} , Amanda de
6	Albuquerque Lopes Machado ¹ , Glória Regina de Góis Monteiro ¹ , lara Marques
7	Medeiros ^{1,2} , Jose Wilton Queiroz ^{1†} , Iraci Duarte Lima ^{1,4} , Richard D. Pearson ⁵ , Mary E.
8	Wilson ⁶ , Marshall J. Glesby ⁷ , Eliana Lúcia Tomaz do Nascimento ^{1,2} , Selma Maria
9	Bezerra Jerônimo ^{1,8,9*}
10	¹ Institute of Tropical Medicine of Rio Grande do Norte, Federal University of Rio Grande
11	do Norte, Natal, RN, Brazil
12	² Department of Infectious Disease, Health Science Center, Federal University of Rio
13	Grande do Norte, Natal, RN, Brazil
14	³ Health Graduate Program, Federal University of Rio Grande do Norte, Natal, RN, Brazil
15	⁴ State of Rio Grande do Norte Health Secretariat, Natal, RN, Brazil
16	⁵ Division of Infectious Diseases and International Health, Department of Medicine,
17	University of Virginia, Charlottesville, VA, USA
18	⁶ Departments of Internal Medicine and Microbiology & Immunology, University of Iowa
19	and the Veterans' Affairs Medical Center, Iowa City, IA, USA
20	⁷ Division of Infectious Disease, Weill Cornell Medical College, New York, NY, USA
21	⁸ Institute of Science and Technology of Tropical Diseases, Natal, RN, Brazil
22	⁹ Department of Biochemistry, Federal University of Rio Grande do Norte, Natal, RN,
23	NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- ²⁴ ^{¶+}COMA and MMA equally contributed to this study.
- ²⁵ [†] In memoriam
- 26 *Corresponding author: Selma Maria Bezerra Jeronimo. Institute of Tropical Medicine of
- 27 Rio Grande do Norte; Universidade Federal do Rio Grande do Norte. Av Salgado Filho
- 28 3000. Campus Universitário. Lagoa Nova. Natal, RN, Brazil. CEP: 59090-040.
- 29 selma.jeronimo@ufrn.br
- 30 Key words: Visceral leishmaniasis, AIDS/VL, HIV, co-infection, T cell activation, T cell
- 31 exhaustion, T cell senescence.

32 Abstract

Background: *Leishmania infantum* is an opportunistic parasitic infection. An immunocompromised state increases the risk of converting asymptomatic infection to symptomatic visceral leishmaniasis (VL), which has a ~5% fatality rate even with treatment. HIV coinfection increases the risk of death from VL.

37 Methods: A cross-sectional study was performed between 2014 and 2016 to

determine the prevalence of *L. infantum* infection in HIV positive subjects residing in

the state of Rio Grande do Norte, Brazil (n=1,372) and of these a subgroup of subjects

40 were followed longitudinally. Subsequent incident cases of VL were ascertained from a

41 public health database through 2018. A subgroup (n=69) of the cross-sectional study

42 subjects was chosen to assess immune status (T cell activation, senescence,

43 exhaustion) and outcome. The data were compared between asymptomatic HIV+/L.

44 infantum+ (HIV/Leish), symptomatic visceral leishmaniasis (VL), recovered VL, DTH+

45 (Delayed-Type Hypersensitivity response – Leishmanin skin test), AIDS/VL, HIV+ only

46 (HIV+), and Non-HIV/Non *L. infantum* infection (control subjects).

Results: The cross-sectional study showed 24.2% of HIV+ subjects had positive anti-47 IgG Leishmania antibodies. After 3 years, 2.4% (8 of 333) of these HIV/Leish coinfected 48 subjects developed AIDS/VL, whereas 1.05% (11 of 1.039) of HIV subjects with negative 49 leishmania serology developed AIDS/VL. Poor adherence to antiretroviral therapy 50 (p=0.0008) or prior opportunistic infections (p=0.0007) was associated with 51 development of AIDS/VL. CD4+ (p=0.29) and CD8+ (p=0.38) T cells counts or viral load 52 (p=0.34) were similar between asymptomatic HIV/Leish and HIV subjects. However, 53 activated CD8+CD38+HLA-DR+ T cells were higher in asymptomatic HIV/Leish than HIV 54 group. Likewise, senescent (CD57⁺) or exhausted (PD1⁺) CD8⁺ T cells were higher in 55 asymptomatic HIV/Leish than in AIDS/VL or HIV groups. 56

57 Conclusion: Although asymptomatic HIV/Leish subjects had normal and similar CD4+ 58 and CD8+ T cells counts, their CD8⁺T cells had increased activation, senescence, and 59 exhaustion, which could contribute to risk of developing VL.

60

61 Author Summary

The frequency of asymptomatic HIV/Leishmania infantum (HIV/Leish) infection and the 62 immunological status of subjects with HIV+ residing in the state of Rio Grande do Norte, 63 Brazil, between 2014 and 2016 were studied. A high frequency of asymptomatic 64 HIV/Leishmania infantum infection (HIV subjects with positive anti-IgG Leishmania 65 66 antibodies) was found. Asymptomatic HIV/Leish subjects had CD8 T cells with higher markers of activation, senescence and exhaustion than the other groups (HIV-alone, 67 symptomatic VL, Recovered VL, DTH+, AIDS/VL and Controls subjects). Poor 68 69 adherence to antiretroviral therapy or history of previous opportunistic infection was associated with AIDS/VL. Asymptomatic HIV/Leish had high relative risk of developing 70 71 AIDS/VL. Thus, subjects with HIV residing in endemic areas for VL should be assessed for their L. infantum infection status and advised to closely adhere to ART. 72

74 Introduction

Visceral leishmaniasis (VL) is a prevalent disease in many countries, with more 75 than 90% of cases in India, Nepal, Bangladesh, Sudan and Brazil. Leishmania infantum 76 is the main etiologic agent of VL in Latin America and Europe [1]. L. infantum infection 77 outcomes vary from asymptomatic to severe disease, but asymptomatic infection occurs 78 in most people. In endemic regions of Brazil, a trend to harbor asymptomatic infection 79 rather than VL has increased in parallel with improvement and nutrition, overall 80 81 vaccination rate for children including measles and sanitary conditions around the household [2-4]. 82

The factors determining the conversion from asymptomatic infection to VL are 83 still not totally understood. Recent studies indicate that high antibody titers are more 84 often see in subjects with symptomatic VL [5,6]. Subsets of T cells from asymptomatic 85 L. infantum infected subjects are capable of activation after Leishmania stimulation, 86 detected by the marker CD69⁺. The majority of asymptomatic subjects mount Th1-type 87 88 cellular immune responses with IL-2 and IFN- γ production that is long-lasting if there is no immunosuppression, possibly indicating protective immunity [7]. In contrast, 89 symptomatic VL subjects have unique T cell responses characterized by exhaustion and 90 activation profiles, with decreased IFN- γ production [8]. 91

The resurgence of VL in Europe occurred concurrently with the HIV epidemic, first spread through sharing of needles, and but also through the expansion of canine VL in several countries including Portugal, Spain, France and Italy. In Brazil, HIV was initially an infection of urban settings and VL was a disease predominantly in rural areas. However, in the last 30 years VL has become frequent in peri-metropolitan areas of major cities in the Northeast and Southeast regions of the country, and HIV has spread to rural areas. The increased regional overlap of both infections has led to changes in the epidemiology of VL due to co-infection [1,4]. In Rio Grande do Norte, this resulted in
an increase in AIDS/VL cases detected after 2010 [3,4].

A high risk of VL is observed among people living with HIV [9], and *L. infantum* is an opportunistic pathogen in this population [10]. The impact of VL in people who are immunocompromised by HIV can be devastating, since both diseases suppress the immune system [11]. Asymptomatic co-infection with HIV and *Leishmania* increases the risk of VL development [12], and in Brazil co-infected patients have had more VL relapses and higher rates of death than singly infected persons [1]. Relapses of VL have been associated with falling CD4⁺ T cell counts [9].

108 Leishmania infection increases HIV viral load in serum from co-infected people [13]. Consistently, macrophages co-infected with HIV in vitro have higher L. infantum 109 loads and increased capacity to uptake the mammalian stage, the amastigote [14,15]. 110 111 Chronic HIV infection is known to lead to CD4⁺ T cell depletion and CD8⁺ T cell activation [11]. Cellular immune responses are essential for control of *Leishmania* spp. infection, 112 with contributions of CD4⁺ T cells to the outcome of active disease and CD8+ cells 113 114 contributing to immune protection. It is possible that the low CD4 T cells characterizing HIV infection synergize with the suppressed hematopoietic cell functions due to 115 116 Leishmania spp. infection [16]. Indeed, AIDS/VL co-infected subjects exhibit increased CD8⁺ T cell activation during active VL disease and after remission compared to singly 117 infected persons [17] and the chronic T cell activation phenotype is positively correlated 118 119 with T cell senescence, accelerating immune cell impairment [16].

Our overarching hypothesis is that people living with asymptomatic HIV-*L. infantum* co-infection have higher risk of developing AIDS/VL than individuals with *L. infantum* infection alone. The goals of the study were to study the immune T cell activation, senescence and exhaustion in co-infected subjects, comparing AIDS/VL and

- asymptomatic HIV/Leishmania subjects with recovered VL, DTH+ (Montenegro skin
- test), AIDS/VL, HIV, and control subjects.

127 Methods

128 Study Design and population

A cross-sectional study was performed between July 2014 and January 2016, in 129 which 1.372 HIV individuals residing in Rio Grande do Norte State, Brazil, which is 130 endemic for VL, were tested for L. infantum infection by SLA and rK39 antigens using 131 ELISA. A retrospective analysis was performed with data on symptomatic VL cases 132 obtained from the Notifiable Diseases Information System (SINAN). All AIDS/VL 133 134 reported cases in SINAN database were cross referenced to 1,372 HIV cases evaluated in cross-sectional study. All cases observed between July 2014 and December 2018 135 were analyzed. This was followed by the study of the immunological status of 69 136 subjects infected with HIV and/or Leishmania. The description of groups in the 137 immunologic study is found in Table 1. All subjects included in immunological study had 138 blood samples collected for further serological evaluation and for immunophenotyping, 139 140 and their clinical data were collected. The subjects were questioned about adherence to ART therapy and previous opportunistic infections. 141

142 **Table 1** – Subject groups undergoing immunologic testing

Group	Group name	n	Definition			
HIV only	HIV	16	HIV subjects on ART, with negative <i>L. infantum</i> serology and no symptoms of VL			
Asymptomatic HIV+/L. infantum+	Asympt HIV/Leish	10	HIV subjects on ART, positive <i>L. infantum</i> serology and no symptoms of VL			
AIDS/VL	AIDS/VL	14	AIDS and symptomatic VL*			
Symptomatic VL	VL	8	Symptomatic VL* and HIV negative			
Recovered VL	Recovered VL	6	Immunocompetent subjects treated for VL who had clinical recovery			

	DTH+		Immunocompetent subjects with DTH skin				
DTH+		9	test response to Leishmania antigens with				
			no history of VL				
Healthy Control	CS	6	Healthy controls with no history of				
Healthy Control	63	6	Leishmania or HIV infections				

143

*The VL status was confirmed by either parasitological findings in the bone marrow aspirate or by presence of anti-Leishmania antibodies and with clinical findings consistent with the disease. 144

ELISA serologic test for asymptomatic *Leishmania* case detection 145

HIV cases were screened for the presence of anti-Leishmania IgG antibodies 146 using two Leishmania infantum antigens. (1) A soluble lysate of L. infantum (SLA) was 147 produced from an isolate from a patient with VL in Natal that was typed in a World Health 148 149 Organization Reference Laboratory (Elisa Cupolillo, Fiocruz, Rio de Janeiro, Brazil). (2) rK39 antigen for ELISA was kindly provided by Steven G. Reed (Infectious Diseases 150 Research Institute, Seattle, WA). Both ELISA protocols have been previously described 151 152 [18,19]. The cutoff for a positive reaction was determined as the mean + three standard deviations of the absorbance of negative control sera (minus absorbance in blank wells). 153 Each serum sample was analyzed in duplicate. The results are shown as relative OD 154 (rOD), normalized to the cutoff for each. The rOD was determined as the (mean of 155 sample duplicates) - (mean absorbance in blank wells) / Cut-off. The results were 156 157 expressed by rOD median/min-max; p value.

Delayed Type Hypersensitivity skin test (DTH) to leishmania antigens 158

159 The antigen used for assessment of the DTH skin test was kindly provided by the 160 Centro de Produção e Pesquisa de Imunobiológico/PR (CPPI, Paraná, Brazil). It was prepared from *L. amazonensis*, and it is the only DTH preparation approved for clinical 161 use in Brazil. The DTH was placed and read in accordance with the ballpoint pen 162 163 technique [20]. Induration greater than 5 mm in diameter was considered positive [21]

Lymphocyte isolation and flow cytometric detection of T cell subsets 164

Two milliliters of peripheral blood were collected and red blood lysis buffer was 165 166 added. After red blood cell lysis, white cells were washed by centrifugation in 0.1% PBS-Azide and then labeled with monoclonal antibodies. Activation status (CD38-FITC; BD, 167 clone HIT2/HLA-DR-PE; Ebioscience, clone L243), Senescence (CD57-FITC; BD, clone 168 NK-1) and Exhaustion (PD-1-PERCP; Biolegend, clone NAT105) were analyzed in 169 CD4⁺CD3⁺ and in CD8⁺CD3⁺ T cells by flow cytometry. After antibody incubation, cells 170 171 were fixed in 1% formol buffer. Thirty thousand events were acquired from each sample using a FACS Canto II flow cytometer (BD, Canto II flow cytometer, Becton Dickinson 172 Bioscience, USA). FlowJo vX software was used for flow cytometry analysis. 173 174 Lymphocytes were gated in forward scatter and side scatter dot plot graphic. Activation, senescence and Exhaustion markers were evaluated in gated CD4+CD3+ and in 175 CD8⁺CD3⁺ T lymphocyte subpopulation. Results were expressed as percentage 176 (median; min-max). 177

178 Ethical considerations

The protocol and informed consent were reviewed and approved by the Federal University of Rio Grande do Norte Ethical Committee (CEP-UFRN) and by the Brazilian National Ethics Committee (CONEP). The certificate of ethical approval is CAAE 12675013.7.0000.5537. Informed consent was obtained, and the consent form was signed by the participant or their legal guardian.

184 Statistical analysis

185 Continuous variables are expressed as medians and interquartile ranges. The 186 statistical analyses were performed using GraphPad Prism software (version 8.0, San 187 Diego, CA, USA). Kruskal-Wallis nonparametric ANOVA with multiple comparisons was 188 used to analyze differences between groups. Differences were considered statistically 189 significant when the p value was <0.05. Chi-square test was performed to compare

190 categorical variables. Relative risk was calculated using omni calculator

- 191 (https://www.omnicalculator.com/statistics/relative-risk) with 95% confidence intervals
- 192 (CI).
- 193

194 **Results**

195 1. Leishmania infection in people living with HIV in endemic area of Rio Grande

do Norte, Brazil, and visceral leishmaniasis development.

People living with HIV (n=1,372) were tested for L. infantum infection, using SLA 197 and rK39 anti-IgG ELISA serology. Of those, 333 people with HIV (24.2%, 333/1,372) 198 had positive antibodies to rK39 and/or SLA. High titers of SLA or rK39 were detected in 199 17.2% (236/1,372) or 12.9% (178/1,372) patients, respectively. SLA rOD results 200 correlated with rK39 rDO (r=0.82; p<0.001). Three years after the initial screening, 19 201 (1.38%) subjects developed visceral leishmaniasis (AIDS/VL) and were treated for VL. 202 203 Among the subjects who developed AIDS/VL, 11 had initially tested negative for Leishmania infection (11 of 1,039; 1.05%) and 8 had tested positive for Leishmania (8 204 205 of 333; 2.4%) (Chi-square; p=0.033) (Table 2).

206 **Table 2** – Relative risk of HIV subjects to development AIDS/VL

	HIV	HIV/SLA-*	HIV/SLA+* (asymptomatic)	Relative Risk	Chi- square
AIDS/VL	19/1,372	11/1,039	8/333	2 27	0 0 2 2
outcome	(1.38%)	(1.05%)	(2.4%)	2.21	0.033

*Relative risk – comparison between HIV/SLA- and HIV/SLA+ groups

208 **2. Immunologic and virologic assessments comparing HIV and HIV**-209 **asymptomatic Leishmania infected group**

The immunologic and virologic status of a subgroup of asymptomatic HIV/Leish subjects was compared to HIV, AIDS/VL, VL, Recovered VL, DTH+ and CS subjects. Results are shown in Table 3, as median (min-max); and in Tables 4 and 5 as *p values*. Most of the subjects were males as VL (87.5%), AIDS/VL (85%) and asymptomatic HIV/Leish individuals (70%) (Table 3). There was no difference in the age between groups (Kruskal-Wallis p=0.56) (Table 3).

Table 3 – Clinical and laboratory characteristics of patients included in the immunologic

Groups	Age	Gender	CD4 ⁺ T cells	CD8⁺ T cells	HIV Viral load	rOD anti-	rOD anti-
	(Years)	(%male)	count	count	(Log ₁₀ copies/mL)	IgG SLA	lgG rK39
			(cells/mm ³)	(cells/mm ³)			
CS	45	3F/3M	ND	ND	ND	0.15	0.29
(n=6)	(35-52)	(50%)	ND	ND	ND	(0.13-0.7)	(0.15-0.7)
HIV	42	7M/9F	620	817	UND	0.17	0.33
(n=16)	(21-54)	(43,7%)	(64-1,153)	(284-1,992)	(UND-3.9)	(0.14-0.49)	(0.16-0.61
Asympt	41	7M/3F	414	1002	UND	1.66	0.96
HIV/Leish (n=10)	(29-62)	(70%)	(105-747)	(316-35,462)	(UND-4.5)	(1.01-3.86)	(0.35-2.97
AIDS/VL	40	12M/2F	85	737	5.3	0.55	0.59
(n=14)	(18-53)	(85%)	(8-161)	(218-1,194)	(UND-7.0)	(0.13-6.17)	(0.19-7.91
VL	35	7M/1F				3.93	5.79
(n=8)	(16-51)	(87,5%)	ND	ND	ND	(1.63- 10.47)	(1.02-9.47
Recovered	28	2F/4M				1.35	1.5
VL (n=9)	(15-32)	(66.67%)	ND	ND	ND	(0.44-3.5)	(0.57- 14.88)
DTH+	36	4M/5F	ND	ND	ND	1.03	1.7
(n=6)	(15-56)	(44.5%)	ND	ND	UNI	(0.66-1.22)	(1.17-3.6)

Results are expressed in Median (min-max); F – female; M – Male; ND – not done; UND –
undetectable (<40 viral copies/mL); rOD – relative OD.

220

217

All asympt HIV/Leish individuals (10 of 10) had positive anti-IgG SLA serology, 221 222 and 5 of 10 individual had positive anti-IgG rK39 serology. Asympt HIV/Leish individuals 223 had higher anti-SLA IgG antibodies and similar levels of anti-rK39 IgG antibodies compared to AIDS/VL (Table 3 and 4). VL patients had higher levels of anti-Leishmania 224 antibodies than AIDS/VL group (SLA and rK39) or DTH+ subjects (SLA). Most AIDS/VL 225 226 subjects had negative serology to Leishmania infantum antigens (SLA: 71.4%/ rK39: 78.5%). DTH+ subjects had similar rOD antibodies levels as asympt HIV/Leish 227 individuals or recovered VL subjects (Table 3 and 4). 228

Table 4 – Comparison of anti-Leishmania antibodies among the groups with respective *p* values

SLA								
p-values	CS	HIV	Asymp HIV/Leish	AIDS/VL	VL	Recovered VL	DTH+	
CS		0.56	0.0001	0.03	<0.0001	0.004	0.007	
HIV			<0.0001	0.0	NC	NC	NC	
Asympt HIV/Leish				0.01	NC	NC	0.19	
AIDS/VL					0.0006	NC	NC	
VL						0.16	0.02	
Recovered VL							0.57	
DTH+								
			rK	(39				
p-values	CS	HIV	Asymp HIV/Leish	AIDS/VL	VL	Recovered VL	DTH+	
CS		0.75	0.01	0.04	<0.0001	0.003	0.0006	
HIV			0.006	0.02	NC	NC	NC	
Asympt HIV/Leish				0.45	NC	NC	0.23	
AIDS/VL					0.002	NC	NC	
VL						0.35	0.31	
Recovered VL							0.093	
DTH+								

230

NC – not compared

HIV groups differed with respect to their HIV viral loads and CD4+ T cell counts, 231 but not their CD8+ T cell counts (Table 3 and 5). HIV and asympt HIV/Leish individuals 232 233 had lower viral loads than individuals with AIDS/VL (Table 3 and 5). At the same time, 234 CD4+ T counts were higher in HIV and in asympt HIV/Leish individuals than in AIDS/VL (table 3 and 5). Viral load, and CD4 and CD8 T cell counts did not differ between HIV 235 and asympt HIV/Leish individuals (Table 3 and 5). HIV viral load correlated negatively 236 to CD4 T cell counts (r=-0.53; p=0.005). No differences in CD8+ T cell counts were 237 observed between the HIV, asympt HIV/Leish and AIDS/VL groups (ANOVA Kruskal-238 Wallis p=0.25) (table 3). 239

240 **Table 5** – Comparison of HIV load and CD4 counts

Viral load								
p-values	HIV	Asympt HIV/Leish	AIDS/VL					
HIV		0.34	<0.0001					
Asympt HIV/Leish			0.004					
AIDS/VL								
CD4 counts								

p-values	HIV	Asympt HIV/Leish	AIDS/VL
HIV		0.29	<0.0001
Asympt HIV/Leish			0.003
AIDS/VL			
NO materiananad			

241 NC – not compared

242

ART was used by 81.25% (13/16) of the HIV subjects (Table 6). However, in 243 244 Leishmania infected groups, the adherence to ART was lower. Sixty percent (6/10) of asympt HIV/Leish subjects and 7.15% (1/14) of AIDS/VL subjects used ART regularly 245 (Table 6). Subjects were asked about their history of prior chronic infections with 246 247 Toxoplasma spp., Mycobacterium tuberculosis or Mycobacterium leprae. Before enrollment, 25% (4/16) of HIV subjects had had these chronic infections, 40% (4/10) of 248 249 asympt HIV/Leish subjects had had previous chronic infections, and 84% (11/14) of 250 AIDS/VL cases had had previous infections (Table 6). Chi-square analysis revealed that both the incorrect use of ART therapy (Fisher Chi-square 0.0008) and a history of 251 previous chronic infection (Fisher Chi-square 0.0007) were associated with an increased 252 253 risk of AIDS/VL outcome (Table 6).

Table 6 – Adherence to ART treatment or previous infection and AIDS/VL outcome association

	HIV	Asympt HIV/Leish	AIDS/VL	Chi- Square
Adherence to ART	13/16 (81.2%)	6/10 (60%)	1/14 (7.1%)	0.0008
Previous chronic infections*	4/16 (25%)	4/10 (40%)	11/14 (84%)	0.0007

256 *toxoplasmosis, tuberculosis, leprosy

257 3. Asymptomatic HIV/Leishmania infantum infection increased activation,

258 senescence and exhaustion immunological status in CD8⁺T cells

- T cell activation, senescence and exhaustion were examined in HIV-subjects.
- The results are shown in table 7 and 8, and Figures 1 and 2.

	CD	3*CD4* T cell		CD	3⁺CD8⁺ T cell	
	CD38 ⁺ HLA-DR ⁺	CD57+	PD1+	CD38 ⁺ HLA-DR ⁺	CD57+	PD1+
CS	2.0%	12.87%	8.65%	2.42%	39.4%	0.04%
(n=6)	(0.8-13.7)	(1.27-37.0)	(3.9-12.9)	(0.54-3.58)	(15.9-60.1)	(0.0-0.55)
HIV	2.52%	4.1%	5.1%	4.19%	39.1%	2.52%
(n=16)	(0.78-17.7)	(0.73-52.2)	(0.18-15.4)	(2.14-25.1)	(17.1-69.6)	(0.01-58.0
Asympt	6.89%	15.65%	5.37%	24.55%	62.8%	42.6%
HIV/Leish (n=10)	(3.31-15.8)	(2.6-66.7)	(1.3-21.4)	(6.65-50.4)	(42.6-88.0)	(15.7-80.1
AIDS/VL	18.89%	10.88%	18.0	36.85%	54.6%	21.45%
(n=14)	(0.74-86.2)	(0.2-40.0)	(0.4-40.2)	(14.7-96.9)	(21.3-72.4)	(6.2-57.0)
VL	14.2%	5.81%	11.7%	54.05%	49.7%	15.15%
(n=8)	(0.85-31.7)	(1.2-28.7)	(0.7-45.9)	(2.08-65.0)	(11.1-59.1)	(4.32-55.7
Recovered	2.7%	6.82%	18.95%	5.41%	43.6%	1.55%
VL (n=9)	(1.34-7.1)	(3.0-47.9)	(5.93-40.1)	(2.77-12.5)	(11.2-71.2)	(0.28-12.2
DTH+	0.39%	8.3%	4.02%	0.08%	35.1%	0.24%
(n=6)	(0.02-1.83)	(0.71-17.6)	(1.82-30.9)	(0.0-7.42)	(12.0-59.6)	(0.0-1.69

Table 7 – Proportions of subjects with makers of immune activation, senescence or exhaustion in T cell subsets

263 Results were expressed Median (Min-Max)

264

265 **Table 8** – Comparison of T cell markers among groups

CD4	4+ T	cell ac	tivation ma	arkers (HI	A-DR, C	CD38)	
p-values	CS	HIV	Asympt HIV/Leish	AIDS/VL	VL	Recovered VL	DTH+
CS		0.99	0.11	0.0008	0.05	0.96	0.09
HIV			0.04	0.0004	NC	NC	NC
Asympt HIV/Leish				0.25	NC	NC	0.0002
AIDS/VL					0.57	NC	NC
VL						0.06	<0.0001
Recovered VL							0.08
DTH+							
CD	8+ T	cell ac	tivation ma	arkers (Hl	_A-DR, C	CD38)	
p-values	CS	HIV	Asympt HIV/Leish	AIDS/VL	VL	Recovered VL	DTH+
CS		0.11	0.0007	<0.0001	0.0001	0.95	0.18
HIV			0.01	0.0001	NC	NC	NC
Asympt HIV/Leish				0.35	NC	NC	0.0001
AIDS/VL					0.84	NC	NC
VL						0.01	<0.0001
Recovered VL							0.13

DTH+							
	CD4	l+ T ce	ell senesce	nce mark	er (CD57	7)	I
			Asympt			Recovered	
p-values	CS	HIV	HIV/Leish	AIDS/VL	VL	VL	DTH+
CS		0.28	0.55	0.71	0.45	0.95	0.38
HIV			0.04	0.05	NC	NC	NC
Asympt HIV/Leish				0.74	NC	NC	0.09
AIDS/VL					0.19	NC	NC
VL						0.49	0.91
Recovered VL							0.41
DTH+							
	CD8	3+ T ce	ell senesce	nce mark	er (CD57	7)	
			Asympt			Recovered	
p-values	CS	HIV	HIV/Leish	AIDS/VL	VL	VL	DTH+
CS		0.98	0.01	0.23	0.57	0.57	0.88
HIV			0.002	0.11	NC	NC	NC
Asympt HIV/Leish				0.12	NC	NC	0.004
AIDS/VL					0.54	NC	NC
VL						0.96	0.42
Recovered VL							0.43
DTH+							
	CD	4+ T c	ell exhaus	tion mark	er (PD1)		
			Asympt			Recovered	
p-values	CS	HIV	HIV/Leish	AIDS/VL	VL	VL	DTH+
CS		0.31	0.91	0.19	0.41	0.08	0.86
HIV			0.18	0.002	NC	NC	NC
Asympt HIV/Leish				0.16	NC	NC	0.75
AIDS/VL					0.65	NC	NC
VL						0.31	0.27
Recovered VL							0.04
DTH+							
	CD	8+ T c	ell exhaus	tion mark	er (PD1)		
			Asympt			Recovered	
p-values	CS	HIV	HIV/Leish	AIDS/VL	VL	VL	DTH+
CS		0.05	<0.0001	0.0001	0.002	0.16	0.54
HIV			0.003	0.01	NC	NC	NC
Asympt HIV/Leish				0.19	NC	NC	< 0.000
AIDS/VL					0.61	NC	NC
VL						0.12	0.006
Recovered VL						V. 12	0.35
DTH+							0.00
NC – not compare	d						

NC – not compared









Figure 1: Immune activation CD38⁺ HLA-DR⁺ status in CD3⁺CD4⁺ (A) and in CD3⁺CD8⁺





270



274

275 CD38 is a marker of cell activation. In HIV infection, it predicts HIV progression

and correlates with high levels of viral load [1]. High levels of activated T cells were 276 277 observed in VL, AIDS/VL and asympt HIV/Leish subjects, using CD38⁺ and HLA-DR⁺ expression as markers of activation ex-vivo (Fig 1 and Table 7 and 8). VL subjects had 278 higher proportions of activated T-cells than DTH+. After cure, recovered VL subjects 279 had comparatively lowered proportions of CD8+CD38+HLA-DR+ activated T cells than 280 those with VL (Fig 1 and Table 7 and 8). Similar higher and activation levels were 281 282 observed between VL and AIDS/VL subjects, in both CD4⁺ and CD8⁺ T cells. VL patients had higher proportions of CD38+HLA-DR+ T cells than CS. There were no differences 283 between T-cell activation in CS subjects compared to HIV subjects, recovered VL or 284 285 DTH+ subjects. AIDS/VL had higher proportions of activated T cells than HIV or CS (Fig. 1; Tables 7 and 8). Asympt HIV/Leish subjects had higher proportions of activated CD8+ 286 T cells than CS subjects (Fig 1; Tables 7 and 8); and also showed higher proportions of 287 288 activated CD4⁺ T cells than HIV or DTH+. Proportions of T cells expressing activation markers did not differ asympt HIV/Leish and AIDS/VL subjects in CD4⁺ or CD8⁺ T cells. 289 290 However, proportions of CD8⁺ T cells expressing activation markers were higher for asympt HIV/Leish subjects compared to HIV or DTH+ (Fig 1; Tables 7 and 8). 291 CD8⁺CD38⁺ T cells seem to play a role in VL and HIV, especially in AIDS/VL and 292 293 asymptomatic HIV/Leishmania co-infected subjects.

294 CD57 is one of the senescence associated molecules. Senescent cells have 295 shorter-ending telomers, that affect cellular function and proliferation. Cancer, chronic 296 infections, autoimmune disease and aging exhibit high levels of senescent cells [22]. 297 Similar percentages of senescent CD4⁺T cells expressing CD57⁺ were observed 298 between most analyzed groups (Fig 2A; Tables 7 and 8). This includes a lack of 299 significant difference between senescence in CD4⁺ and CD8⁺ T cells of asympt 300 HIV/Leish and AIDS/VL subjects. Nonetheless there were significantly lower proportions

of senescent CD4⁺T cells in HIV group than asympt HIV/Leish or in AIDS/VL subjects 301 302 (Fig 2A; Tables 7 and 8). Proportions of senescent CD8⁺T cells were significantly different across the HIV and VL groups (Fig 2A; Tables 7 and 8). Asympt HIV/Leish 303 expressed higher proportions of CD57⁺CD8⁺ T cells than CS, HIV and DTH⁺ groups. 304 Similar levels of senescent TCD8+ cells were observed in subjects with AIDS/VL, HIV, 305 asympt, HIV/Leish or VL. Even after cure, recovered VL subjects showed similar levels 306 307 of senescent CD8 T cells compared to VL patients (Fig 2A; Tables 7 and 8). Thus, more CD4⁺ and CD8⁺ T cells became senescent in persons with Leishmania and HIV co-308 infection than in asymptomatic HIV/Leish subjects. 309

310 Chronic T activation, such as occurs in HIV infection or visceral leishmaniasis, leads to cell exhaustion. Exhausted cells are dysfunctional and have reduced responses 311 312 to antigen. PD-1 (CD279) is mainly associated exhaustion [22]. Proportions of CD4⁺T 313 expressing this marker of exhaustion in AIDS/VL subjects were significantly higher than among HIV subjects (Fig 2B; Tables 7 and 8). Remarkably there were few other 314 significant differences in CD4+ T cell exhaustion markers between the groups (Fig 2B; 315 316 Tables 7 and 8). In contrast to CD4+ T cells, the overall proportions of CD8⁺T cells expressing the exhaustion marker differed significantly across the groups (Fig 2B; 317 318 Tables 7 and 8). Proportions were highest in the asympt HIV/Leish group, which differed from proportions in HIV, DTH+ or CS subjects. Levels of CD8+ T cell exhaustion were 319 also high in HIV, AIDS/VL and VL subjects. AIDS/VL had similar proportions of 320 exhausted CD8⁺ T compared to VL or asympt HIV/Leish subjects (Fig 2B; Tables 7 and 321 8). However, AIDS/VL had higher proportions than HIV or CS. VL patients had higher 322 senescent CD8⁺T cells than DTH+ or CS. After cure of VL (recovered VL), the levels of 323 CD8⁺PD1⁺ T cells were similar to those in CS and DTH+ subjects (Fig 2B; Tables 7 and 324 8). CS subjects had lower percentages of senencent CD8⁺T cells than HIV subjects. 325

- 326 Thus, CD8⁺T cells of HIV/L. infantum subjects seem to be compromised with high
- 327 senescence and exhaustion levels.

329 Discussion

The urbanization of *L. infantum* in northeastern Brazil and the spread of HIV have contributed to the likelihood of concurrent infections. Since 2010, an increase in AIDS/VL cases as well as in asymptomatic *L. infantum* infection have been observed in the outskirts of Natal, as shown in this study, and in other Brazilian cities [23,24].

Herein we report a high prevalence (24.2%) of *L. infantum* positive serology 334 335 among HIV-infected residents of Natal. Asymptomatic HIV/Leishmania prevalence reported from other endemic areas for VL has ranged from 3% to 25% [25-27]. 336 Differences in the sensitivity and specificity of Leishmania detection tests can affect the 337 338 calculated prevalence of asymptomatic HIV/Leishmania co-infection [28]. Sensitive PCR showed high prevalence of asymptomatic HIV/Leishmania co-infection in Italy [25]. In 339 our study, rK39 and SLA ELISA were used to screen the HIV+ population. The results 340 341 in this study are similar to those previously observed from Natal [19]. It is well known that AIDS/VL patients have lower titers of anti-Leishmania antibodies than persons with 342 VL alone [29]. Of note, asymptomatic HIV/Leish (HIV subject with no clinical or 343 344 laboratorial sign of L. infantum infection but positive serology) have an increased risk of developing AIDS/VL. 345

Asymptomatic HIV/Leish and AIDS/VL subjects in this study were predominately males. The prevalence of HIV is higher among males than females in the state of Grande do Norte. But VL has also been recognized more often in males [4,30]; while both sexes have been shown to be equally exposed to *L. infantum* infection in the region [31]. Sexual hormones seem to play a role in the pathogenesis and progression to VL, once males reach puberty. And higher levels of IL10 and TNF have been observed in male than female mice infected with *Leishmania infantum* [32].

The consequence of HIV and Leishmania infantum co-infection is an increased 353 354 likelihood of progression to AIDS/VL.[1]. The negative correlation between CD4 T cells counts and HIV viral load suggests a spectrum among HIV-infected subjects from 355 asymptomatic HIV/Leish to AIDS/VL. In our study persons with asymptomatic HIV/Leish 356 had similar CD4 and CD8 T cells counts and HIV viral loads as HIV subjects. The lack 357 of adherence to ART therapy or a history of prior infectious diseases were associated 358 359 with an increased risk of progressing to AIDS/VL. Adherence to ART could be maintaining protective Th1 cytokine production by CD4⁺T cells [33]. 360

T cell activation is strongly associated with progression to AIDS and death [34]. In the present study chronic immune activation was observed in AIDS/VL subjects in comparison to HIV+ or negative subjects. The positive correlation between *Leishmania* infection and higher levels of CD8⁺T activation in HIV-co-infected subjects in comparison to those with HIV alone suggests that *L. infantum* plays a role in CD8+T cell activation during co-infections [35].

Leishmania infantum infection causes several immunological alterations 367 contributing to immune suppression. Both VL and AIDS/VL subjects had higher 368 percentages of ex vivo activation. Persons with symptomatic leishmaniasis have 369 370 previously been shown to have higher percentages of ex vivo activation, but it is not Leishmania specific, since CD4⁺T and CD8⁺T cells exposed to leishmanial antigen did 371 not express activation molecules [8]. Despite lower ex vivo activation observed in DTH+ 372 373 or recovered-VL subjects, these groups mounted specific T cell response after stimulation [8]. It is probably that asymptomatic HIV/Leishmania subjects can mount a 374 specific Th1 response to SLA antigen [36], since asymptomatic HIV/Leish subjects 375 showed similar percentage of activated CD4⁺T when compared to HIV or DTH+ 376 individuals, and lower CD4⁺T levels of activation than AIDS/VL subjects. 377

Higher percentages of senescent CD8⁺T(CD3⁺CD8⁺CD57⁺) or exhausted (PD1⁺) 378 379 CD4⁺ or CD8⁺ T cells were found in AIDS/VL than in HIV or control subjects, illustrating the deleterious impact of dual HIV and Leishmania infections, increasing senescence 380 and exhaustion, and consequently, the deterioration of the immune system [1]. In this 381 study, higher percentages of senescence (CD57⁺) and exhaustion (PD1⁺) were 382 observed in the VL and AIDS/VL groups. But senescence was not affected in 383 384 immunocompetent groups, suggesting that it was caused by HIV. During active VL, more exhausted CD8⁺T cells were observed than in persons who had recovered from 385 VL or DTH+ subjects. Exhausted CD8⁺T cells from active VL patients did not produce 386 IFN- γ in response to specific stimulation; however, this suppression was transitory, since 387 after treatment, CD8⁺T cells recover the capacity of specific response [37]. 388

Asymptomatic HIV/Leish co-infected subjects seemed to be controlling both infections. This group did not have any VL symptoms and had similar HIV viral load, CD4 and CD8 T cell counts in comparison to HIV subjects. These similarities in clinical and laboratory findings of asymptomatic HIV/Leish co-infection may be due to properly CD4⁺T cells counts and HIV viral load [25]. But chronic active *Leishmania* infection can stimulate immune activation [17] leading to increase HIV viral load and accelerating progression to AIDS/VL [11,38].

The management of asymptomatic HIV/Leishmania co-infected subjects starts with optimizing ART therapy and close follow-up of clinical status, viral load and CD4 count. Persons who develop symptoms of VL should be treated with liposomal amphotericin or alternative anti-leishmanial therapy. The role of anti-leishmanial therapy in the asymptomatic co-infected person is uncertain. Further studies are needed to determine its role, particularly in persons with low or falling CD4 counts or uncontrolled viral loads.

403 **Acknowledegment:**

- 404 We are thankful to the health personnel from Giselda Trigueiro Hospital, Central
- Laboratory (Laboratório Central de Saúde Pública do Rio Grande do Norte Dr. Almino
- 406 Fernandes) for helping with the volunteers' recruitment.
- 407

408 FINANCIAL SUPPORT

The work was supported in part from a grant from the CNPq (universal 406076/20219); National Institutes of Health (NIH). Project number: AI 136032; National Institute of
Science and Technology in Tropical Diseases (INCT-DT) – Ministério de Ciência,

412 Tecnologia e Inovação, CNPg. Project Number: 465229/2014-0

413

415 **References**

- Lindoso JAL, Moreira CHV, Cunha MA, Queiroz IT. Visceral leishmaniasis and
 HIV coinfection: Current perspectives. HIV/AIDS Res Palliat Care. 2018;10: 193–
 201. doi:10.2147/HIV.S143929
- Lima ID, Queiroz JW, Lacerda HG, Queiroz PVSS, Pontes NN, Barbosa JDAA, et
 al. Leishmania infantum chagasi in Northeastern Brazil: Asymptomatic infection
 at the urban perimeter. Am J Trop Med Hyg. 2012;86: 99–107.
 doi:10.4269/ajtmh.2012.10-0492
- Lima ÁLM, de Lima ID, Coutinho JFV, de Sousa ÚPST, Rodrigues MAG, Wilson
 ME, et al. Changing epidemiology of visceral leishmaniasis in northeastern Brazil:
 A 25-year follow-up of an urban outbreak. Trans R Soc Trop Med Hyg. 2017;111:
 440–447. doi:10.1093/trstmh/trx080
- 4. Lima ID, Lima ALM, Mendes-Aguiar CO, Coutinho JF V, Wilson ME, Pearson RD, 427 et al. Changing demographics of visceral leishmaniasis in northeast Brazil: 428 future. PLoS Negl Trop Dis. 2018;12: 429 Lessons for the e0006164. doi:10.1371/journal.pntd.0006164 430
- 431 5. Chakravarty J, Hasker E, Kansal S, Singh OP, Malaviya P, Singh APAK, et al.
 432 Determinants for progression from asymptomatic infection to symptomatic
 433 visceral leishmaniasis: A cohort study. PLoS Negl Trop Dis. 2018;13: 1–12.
 434 doi:10.1371/journal.pntd.0007216
- Hasker E, Malaviya P, Gidwani K, Picado A, Ostyn B, Kansal S, et al. Strong
 Association between Serological Status and Probability of Progression to Clinical
 Visceral Leishmaniasis in Prospective Cohort Studies in India and Nepal. PLoS
 Negl Trop Dis. 2014;8: 19. doi:10.1371/journal.pntd.0002657
- Ibarra-Meneses A V., Mondal D, Alvar J, Moreno J, Carrillo E. Cytokines and
 chemokines measured in dried SLA-stimulated whole blood spots for
 asymptomatic Leishmania infantum and Leishmania donovani infection. Sci Rep.
 2017;7: 1–7. doi:10.1038/s41598-017-17315-z
- 8. Rodrigues-Neto JF, Monteiro GR, Keesen TSL, Lacerda HG, Carvalho EM,
 Jeronimo SMB. CD45RO+ T cells and T cell activation in the long-lasting immunity

445 after leishmania infantum infection. Am J Trop Med Hyg. 2018;98: 875–882.
446 doi:10.4269/ajtmh.16-0747

- Alvar J, Aparicio P, Aseffa A, Den Boer M, Canavate C, Dedet JP, et al. The
 relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol
 Rev. 2008;21: 334–59, table of contents. doi:10.1128/CMR.00061-07
- Alvar J, Cañavate C, Gutiérrez-Solar B, Jiménez M, Laguna F, López-Vélez R, et
 al. Leishmania and human immunodeficiency virus coinfection: The first 10 years.
 Clin Microbiol Rev. 1997;10: 298–319. doi:10.1128/cmr.10.2.298
- Lindoso JA, Cota GF, da Cruz AM, Goto H, Maia-Elkhoury AN, Romero GA, et al.
 Visceral leishmaniasis and HIV coinfection in Latin America. PLoS Negl Trop Dis.
 2014;8: e3136. doi:10.1371/journal.pntd.0003136
- 456 12. van Griensven J, Zijlstra EE, Hailu A. Visceral Leishmaniasis and HIV Coinfection: Time for Concerted Action. PLoS Negl Trop Dis. 2014;8: 1–2. 457 458 doi:10.1371/journal.pntd.0003023
- 459 13. Preiser W, Cacopardo B, Nigro L, Braner J, Nunnari A, Doerr W, et al.
 460 Immunological findings in HIV/Leishmania coinfection. Intervirology. 1996;39:
 461 285–288. doi:10.1159/000150531
- 14. Zhao C, Thibault S, Messier N, Ouellette M, Papadopoulou B, Tremblay MJ. In 462 human monocyte-derived macrophages exposed 463 primarv to Human immunodeficiency virus type 1, does the increased intracellular growth of 464 Leishmania infantum rely on its enhanced uptake? J Gen Virol. 2006;87: 1295-465 1302. doi:10.1099/vir.0.81647-0 466
- 15. 467 Barreto-de-Souza V, Pacheco GJ, Silva AR, Castro-Faria-Neto HC, Bozza PT, Saraiva EM, et al. Increased Leishmania replication in HIV-1-infected 468 469 macrophages is mediated by tat protein through cyclooxygenase-2 expression 470 and prostaglandin E2 synthesis. J Infect Dis. 2006:194: 846-854. doi:10.1086/506618 471
- 472 16. Casado JL, Abad-Fernandez M, Moreno S, Perez-Elias MJ, Moreno A, Bernardino
 473 JI, et al. Visceral leishmaniasis as an independent cause of high immune
 474 activation, T-cell senescence, and lack of immune recovery in virologically

475 suppressed HIV-1-coinfected patients. HIV Med. 2015;16: 240–248.
476 doi:10.1111/hiv.12206

- 477 17. Santos-Oliveira JR, Regis EG, Giacoia-Gripp CB, Valverde JG, Alexandrino-de478 Oliveira P, Lindoso JA, et al. Microbial translocation induces an intense
 479 proinflammatory response in patients with visceral leishmaniasis and HIV type 1
 480 coinfection. J Infect Dis. 2013/03/30. 2013;208: 57–66. doi:10.1093/infdis/jit135
- 18. Lima ID, Queiroz JW, Lacerda HG, Queiroz PVS, Pontes NN, Barbosa JDA, et al. 481 Leishmania infantum chagasi in Northeastern Brazil: Asymptomatic infection at 482 99–107. the urban perimeter. J Trop Med Hyg. 2012;86: 483 Am doi:10.4269/ajtmh.2012.10-0492 484
- Braz RFS, Nascimento ET, Martins DRA, Wilson ME, Pearson RD, Reed SG, et
 al. The sensitivity and specificity of Leishmania chagasi recombinant K39 antigen
 in the diagnosis of American visceral leishmaniasis and in differentiating active
 from subclinical infection. Am J Trop Med Hyg. 2002;67: 344–348.
 doi:10.4269/ajtmh.2002.67.344
- 490 20. Sokal JE. Measurement of Delayed Skin-Test Responses.
 491 http://dx.doi.org/101056/NEJM197509042931013. 1975;293: 501–502.
 492 doi:10.1056/NEJM197509042931013
- Melo MN , Mayrink W , da Costa CA , Magalhaes PA , Dias M , Williams P , Araujo
 FG , Coelho MV BS. Standardization of the Montenegro antigen. Rev Inst Med
 TropSao Paulo. 1977;19: 161–164. Available: https://www.imt.usp.br/wpcontent/uploads/revista/vol19/161-164.pdf
- 497 22. Crespo J, Sun H, Welling TH, Tian Z, Zou W. T cell anergy, exhaustion,
 498 senescence, and stemness in the tumor microenvironment. Curr Opin Immunol.
 499 2013;25: 214–221. doi:10.1016/j.coi.2012.12.003
- Carranza-Tamayo CO, Assis TSM de, Neri ATB, Cupolillo E, Rabello A, Romero
 GAS. Prevalence of Leishmania infection in adult HIV/AIDS patients treated in a
 tertiary-level care center in Brasilia, Federal District, Brazil. Trans R Soc Trop Med
 Hyg. 2009;103: 743–748. doi:10.1016/j.trstmh.2009.01.014
- 504 24. Orsini M, Canela JR, Disch J, Maciel F, Greco D, Toledo A, et al. High frequency

of asymptomatic Leishmania spp. infection among HIV-infected patients living in
 endemic areas for visceral leishmaniasis in Brazil. Trans R Soc Trop Med Hyg.
 2012;106: 283–288. doi:10.1016/j.trstmh.2012.01.008

- 25. Colomba C, Saporito L, Vitale F, Reale S, Vitale G, Casuccio A, et al. Cryptic
 Leishmania infantum infection in Italian HIV infected patients. BMC Infect Dis.
 2009;9. doi:10.1186/1471-2334-9-199
- Rezaei Z, Sarkari B, Dehghani M, Layegh Gigloo A, Afrashteh M. High frequency
 of subclinical Leishmania infection among HIV-infected patients living in the
 endemic areas of visceral leishmaniasis in Fars province, southern Iran. Parasitol
 Res. 2018;117: 2591–2595. doi:10.1007/s00436-018-5949-9

Ena J, Pasquau F, Del Mar LóPez-Perezagua M, Martinez-Peinado C, Arjona F.
Screening for subclinical leishmania infection in HIV-infected patients living in
eastern Spain. Pathog Glob Health. 2014;108: 356–361.
doi:10.1179/2047773214Y.0000000164

- Echchakery M, Nieto J, Boussaa S, El Fajali N, Ortega S, Souhail K, et al.
 Asymptomatic carriers of Leishmania infantum in patients infected with human immunodeficiency virus (HIV) in Morocco. Parasitol Res. 2018;117: 1237–1244.
 doi:10.1007/s00436-018-5805-y
- Nascimento ET, Moura MLN, Queiroz JW, Barroso AW, Araujo AF, Rego EF, et
 al. The emergence of concurrent HIV-1/AIDS and visceral leishmaniasis in
 Northeast Brazil. Trans R Soc Trop Med Hyg. 2011;105: 298–300.
 doi:10.1016/j.trstmh.2011.01.006

Silva de Lima UR, Vanolli L, Moraes EC, Ithamar JS, Pedrozo e Silva de Azevedo
C de M. Visceral leishmaniasis in Northeast Brazil: What is the impact of HIV on
this protozoan infection? PLoS One. 2019;14: 1–14.
doi:10.1371/journal.pone.0225875

Jeronimo SM, Duggal P, Braz RF, Cheng C, Monteiro GR, Nascimento ET, et al.
An emerging peri-urban pattern of infection with Leishmania chagasi, the
protozoan causing visceral leishmaniasis in northeast Brazil. Scand J Infect Dis.
2004;36: 443–449. Available: http://www.ncbi.nlm.nih.gov/pubmed/15307565

32. Rodriguez NE, Lima ID, Dixit UG, Turcotte EA, Lockard RD, Batra-Sharma H, et
al. Epidemiological and experimental evidence for sex-dependent differences in
the outcome of Leishmania infantum Infection. Am J Trop Med Hyg. 2018;98:
142–145. doi:10.4269/ajtmh.17-0563

- 539 33. De la Rosa R, Pineda JA, Delgado J, Macías J, Morillas F, Mira JA, et al. Incidence 540 of and risk factors for symptomatic visceral leishmaniasis among human immunodeficiency virus type 1-infected patients from Spain in the era of highly 541 active antiretroviral therapy. J Clin Microbiol. 2002;40: 762-767. 542 doi:10.1128/JCM.40.3.762-767.2002 543
- 34. Hunt PW, Martin JN, Sinclair E, Bredt B, Hagos E, Lampiris H, et al. T cell
 activation is associated with lower CD4+ T cell gains in human immunodeficiency
 vires-infected patients with sustained viral suppression during antiretroviral
 therapy. J Infect Dis. 2003;187: 1534–1543. doi:10.1086/374786
- Santos-Oliveira JR, Giacoia-Gripp CBW, Alexandrino de Oliveira P, Amato VS,
 Lindoso JATL, Goto H, et al. High levels of T lymphocyte activation in LeishmaniaHIV-1 co-infected individuals despite low HIV viral load. BMC Infect Dis.
 2010/12/22. 2010;10: 358. doi:10.1186/1471-2334-10-358
- 36. Botana L, Ibarra-Meneses AV, Sánchez C, Castro A, Martin JVS, Molina L, et al.
 Asymptomatic immune responders to Leishmania among HIV positive patients.
 PLoS Negl Trop Dis. 2019;13: 1–14. doi:10.1371/journal.pntd.0007461
- 37. Gautam S, Kumar R, Singh N, Singh AK, Rai M, Sacks D, et al. CD8 T cell
 exhaustion in human visceral leishmaniasis. J Infect Dis. 2014;209: 290–299.
 doi:10.1093/infdis/jit401
- 38. Okwor I, Uzonna JE. The immunology of Leishmania/HIV co-infection. Immunol
 Res. 2013;56: 163–171. doi:10.1007/s12026-013-8389-8